SK82094A3 - Pharmaceutical composition for prevention and/or treatment of gastrointestinal illnesses and also ulcers - Google Patents

Pharmaceutical composition for prevention and/or treatment of gastrointestinal illnesses and also ulcers Download PDF

Info

Publication number: SK82094A3
Authority: SK; Slovakia
Prior art keywords: hydroxypropoxy; group; cyclohexane; imino; chlorophenylmethylene
Prior art date: 1993-07-20

Application number

SK820-94A

Other languages

English (en)

Slovak (sk)

Inventor

Eniko K Szirt

Zoltan Budai

Tibor Mezei

Gabor Blasko

Klara D Kazo

Andras Egyed

Gabor Gigler

Marton Fekete

Klara E Reiter

Gyula Simig

Katalin Szemeredi

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-07-20

Filing date

1994-07-08

Publication date

1995-07-11

1994-07-08 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

1995-07-11 Publication of SK82094A3 publication Critical patent/SK82094A3/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
208000025865 Ulcer Diseases 0.000 title claims description 15
231100000397 ulcer Toxicity 0.000 title claims description 14
230000002496 gastric effect Effects 0.000 title description 13
238000011282 treatment Methods 0.000 title description 7
230000002265 prevention Effects 0.000 title description 3
230000000694 effects Effects 0.000 claims abstract description 20
239000002253 acid Substances 0.000 claims abstract description 19
239000000203 mixture Substances 0.000 claims abstract description 17
239000001257 hydrogen Substances 0.000 claims abstract description 16
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 16
230000002178 gastroprotective effect Effects 0.000 claims abstract description 14
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 13
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 13
230000003287 optical effect Effects 0.000 claims abstract description 12
125000001453 quaternary ammonium group Chemical group 0.000 claims abstract description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 6
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims abstract description 5
125000004070 6 membered heterocyclic group Chemical group 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 51
-1 methoxyphenyl group Chemical group 0.000 claims description 27
239000004480 active ingredient Substances 0.000 claims description 15
150000003997 cyclic ketones Chemical class 0.000 claims description 12
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002431 hydrogen Chemical class 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
125000000753 cycloalkyl group Chemical group 0.000 claims description 4
125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 3
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
125000004193 piperazinyl group Chemical group 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
125000000873 4-chlorophenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C(Cl)C([H])=C1[H] 0.000 claims 3
125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
125000004889 1-methylethylamino group Chemical group CC(C)N* 0.000 claims 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical group C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
230000000845 anti-microbial effect Effects 0.000 abstract description 4
230000000767 anti-ulcer Effects 0.000 abstract description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
239000003814 drug Substances 0.000 abstract description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
UDIWCXFCQWWTTN-UHFFFAOYSA-N 1-amino-3-[(2-benzylidenecyclohexylidene)amino]oxypropan-2-ol Chemical compound NCC(O)CON=C1CCCCC1=CC1=CC=CC=C1 UDIWCXFCQWWTTN-UHFFFAOYSA-N 0.000 abstract 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
238000012360 testing method Methods 0.000 description 21
230000005764 inhibitory process Effects 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
241000590002 Helicobacter pylori Species 0.000 description 11
230000003628 erosive effect Effects 0.000 description 11
238000000034 method Methods 0.000 description 11
230000001120 cytoprotective effect Effects 0.000 description 9
229940037467 helicobacter pylori Drugs 0.000 description 9
230000027119 gastric acid secretion Effects 0.000 description 8
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 7
FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 7
229950009533 cetraxate Drugs 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
229960000381 omeprazole Drugs 0.000 description 6
208000018522 Gastrointestinal disease Diseases 0.000 description 5
239000002775 capsule Substances 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
229960001380 cimetidine Drugs 0.000 description 4
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
208000000718 duodenal ulcer Diseases 0.000 description 4
239000000243 solution Substances 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
208000007107 Stomach Ulcer Diseases 0.000 description 3
125000003545 alkoxy group Chemical group 0.000 description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000008298 dragée Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000005303 weighing Methods 0.000 description 3
229940100445 wheat starch Drugs 0.000 description 3
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
206010017865 Gastritis erosive Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010030216 Oesophagitis Diseases 0.000 description 2
108010059993 Vancomycin Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000007059 acute toxicity Effects 0.000 description 2
231100000403 acute toxicity Toxicity 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
229960003942 amphotericin b Drugs 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
210000002249 digestive system Anatomy 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
201000005917 gastric ulcer Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229960000282 metronidazole Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
229960004633 pirenzepine Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229960003165 vancomycin Drugs 0.000 description 2
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
244000248349 Citrus limon Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
208000015877 Duodenal disease Diseases 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010061164 Gastric mucosal lesion Diseases 0.000 description 1
206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000589989 Helicobacter Species 0.000 description 1
206010019375 Helicobacter infections Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
102000003710 Histamine H2 Receptors Human genes 0.000 description 1
108090000050 Histamine H2 Receptors Proteins 0.000 description 1
OKIBNKKYNPBDRS-UHFFFAOYSA-N Mefluidide Chemical compound CC(=O)NC1=CC(NS(=O)(=O)C(F)(F)F)=C(C)C=C1C OKIBNKKYNPBDRS-UHFFFAOYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 1
238000011785 NMRI mouse Methods 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
108010083204 Proton Pumps Proteins 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000009858 acid secretion Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000005576 amination reaction Methods 0.000 description 1
229960003022 amoxicillin Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003288 anthiarrhythmic effect Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003257 anti-anginal effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
208000026555 breast adenosis Diseases 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
208000015864 chronic erosive gastritis Diseases 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
APGUSRKQFBWUPZ-UHFFFAOYSA-K disulfooxyalumanyl hydrogen sulfate Chemical compound [Al+3].OS([O-])(=O)=O.OS([O-])(=O)=O.OS([O-])(=O)=O APGUSRKQFBWUPZ-UHFFFAOYSA-K 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007905 drug manufacturing Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000002864 food coloring agent Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
150000002443 hydroxylamines Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
229960000620 ranitidine Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229960004291 sucralfate Drugs 0.000 description 1
MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000004448 titration Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Reinforced Plastic Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK820-94A 1993-07-20 1994-07-08 Pharmaceutical composition for prevention and/or treatment of gastrointestinal illnesses and also ulcers SK82094A3 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU9302081A HU213472B (en)	1993-07-20	1993-07-20	Process to preparare pharmaceutical compns. with gastroprotective and anti helicobacter pylori activity

Publications (1)

Publication Number	Publication Date
SK82094A3 true SK82094A3 (en)	1995-07-11

Family

ID=10983801

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK820-94A SK82094A3 (en)	1993-07-20	1994-07-08	Pharmaceutical composition for prevention and/or treatment of gastrointestinal illnesses and also ulcers

Country Status (14)

Country	Link
EP (1)	EP0636368B1 (de)
JP (1)	JPH0769875A (de)
AT (1)	ATE160937T1 (de)
CA (1)	CA2128354A1 (de)
CZ (1)	CZ167494A3 (de)
DE (1)	DE69407227D1 (de)
HR (1)	HRP940361A2 (de)
HU (1)	HU213472B (de)
IL (1)	IL110369A0 (de)
IT (1)	IT1274040B (de)
PL (1)	PL304334A1 (de)
RU (1)	RU94026275A (de)
SK (1)	SK82094A3 (de)
YU (1)	YU45994A (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU197205B (en) *	1984-07-10	1989-03-28	Egyt Gyogyszervegyeszeti Gyar	Process for production of medical compositions against angine
HU212415B (en) *	1989-08-25	1996-06-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing new cyclic oxym derivatives and pharmaceutical compositions containing them as active components

1993
- 1993-07-20 HU HU9302081A patent/HU213472B/hu not_active IP Right Cessation
1994
- 1994-06-21 HR HRP9302081A patent/HRP940361A2/xx not_active Application Discontinuation
- 1994-07-08 SK SK820-94A patent/SK82094A3/sk unknown
- 1994-07-12 CZ CZ941674A patent/CZ167494A3/cs unknown
- 1994-07-18 DE DE69407227T patent/DE69407227D1/de not_active Expired - Lifetime
- 1994-07-18 EP EP94111107A patent/EP0636368B1/de not_active Expired - Lifetime
- 1994-07-18 AT AT94111107T patent/ATE160937T1/de not_active IP Right Cessation
- 1994-07-18 PL PL94304334A patent/PL304334A1/xx unknown
- 1994-07-19 YU YU45994A patent/YU45994A/sh unknown
- 1994-07-19 CA CA002128354A patent/CA2128354A1/en not_active Abandoned
- 1994-07-19 IL IL11036994A patent/IL110369A0/xx unknown
- 1994-07-20 JP JP6168018A patent/JPH0769875A/ja active Pending
- 1994-07-20 IT ITMI941518A patent/IT1274040B/it active IP Right Grant
- 1994-07-20 RU RU94026275/14A patent/RU94026275A/ru unknown

Also Published As

Publication number	Publication date
DE69407227D1 (de)	1998-01-22
YU45994A (sh)	1997-12-05
ITMI941518A0 (it)	1994-07-20
IT1274040B (it)	1997-07-14
HU9302081D0 (en)	1993-10-28
EP0636368B1 (de)	1997-12-10
HRP940361A2 (en)	1997-02-28
IL110369A0 (en)	1994-10-21
EP0636368A1 (de)	1995-02-01
CA2128354A1 (en)	1995-01-21
JPH0769875A (ja)	1995-03-14
ATE160937T1 (de)	1997-12-15
CZ167494A3 (en)	1995-03-15
HUT69166A (en)	1995-08-28
RU94026275A (ru)	1996-09-10
HU213472B (en)	1997-06-30
PL304334A1 (en)	1995-01-23
ITMI941518A1 (it)	1996-01-20

Publication	Publication Date	Title
JP4818516B2 (ja)	2011-11-16	化合物の抗菌剤としての新規な使用
US6306904B1 (en)	2001-10-23	Antihistaminic/antitussive compositions
SK280283B6 (sk)	1999-11-08	Farmaceutický prostriedok na liečenie žalúdočných
US5843987A (en)	1998-12-01	Method of stimulating gastrointestinal motility with ellagic acid
CA2372538A1 (en)	2003-08-18	Antitussive/antihistaminic/decongestant compositions
ZA200100913B (en)	2002-05-02	New compounds.
EP1123702A1 (de)	2001-08-16	Analgetika
CN114732818B (zh)	2023-02-10	一种抗特发性肺纤维化药物尼达尼布在结核病治疗中的应用
JP3593357B2 (ja)	2004-11-24	抗菌剤
WO2023150547A3 (en)	2023-09-14	Psychedelic compounds and their therapeutic uses
US6017950A (en)	2000-01-25	Methods for controlling gram negative bacteria in mammals
SK82094A3 (en)	1995-07-11	Pharmaceutical composition for prevention and/or treatment of gastrointestinal illnesses and also ulcers
KR20010024050A (ko)	2001-03-26	항균제
US5597822A (en)	1997-01-28	Pharmaceutical compositions for the prevention and/or treatment a gastrointestinal diseases
JPS58189114A (ja)	1983-11-04	抗潰瘍剤
CN1230176C (zh)	2005-12-07	4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并[2,3－d]嘧啶用于制备治疗疼痛的药物的应用
US20060160887A1 (en)	2006-07-20	Medicinal composition
KR100416066B1 (ko)	2004-01-24	구아니디노메틸 사이클로헥산 카복실산 에스테르 유도체
CA2464119A1 (en)	2003-05-01	Antihistaminic/antitussive compositions
JPWO1996006825A1 (ja)	1997-07-29	グアニジノメチルシクロヘキサンカルボン酸エステル誘導体
US3933999A (en)	1976-01-20	Organic compounds
EP0697215A1 (de)	1996-02-21	Mittel gegen verdauungsbeschwerden
US6362169B1 (en)	2002-03-26	Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
CA2372535A1 (en)	2003-08-18	Antitussive compositions
JP3386873B2 (ja)	2003-03-17	消化器系疾患用剤